Tanespimycin Production Cost Reports

The report provides a detailed analysis essential for establishing a tanespimycin manufacturing plant. It encompasses all critical aspects necessary for tanespimycin production, including the cost of tanespimycin production, tanespimycin plant cost, tanespimycin production costs, and the overall tanespimycin manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a tanespimycin production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Tapespimycin is a well-known HSP90 inhibitor majorly associated with the healthcare and medical industry, for cancer treatment. It is an antibiotic derived from geldanamycin that works by reducing the function of the HSP90 protein. The protein is involved in the folding and stabilization of several other proteins required for cancer cell growth and survival.

Tanespimycin, by inhibiting HSP90, can destabilize these client proteins and cause their degradation, resulting in tumor development and cell death suppression. It has been investigated as a potential treatment for a variety of cancers, including lung, breast, prostate, and pancreatic cancer.

It has had encouraging effects in preclinical research and has been evaluated in a number of clinical trials, both as a monotherapy and in combination with other medications. Tanespimycin is a promising novel cancer treatment method that has been demonstrated to be beneficial when used in conjunction with other cancer treatments such as chemotherapy, etc.

The market for tapespimycin is strongly influenced by its demand for the production of medications prepared for cancer treatment. The applications of tapespimycin as an antibiotic or HSP90 inhibitor in medications for cancer treatment drive its demand in the healthcare and medical industry.

Its effectiveness in combination with other cancer treatment techniques, including chemotherapy, etc., increases its demand in the market. The procurement of tapesinmycin is dependent upon factors including its demand in the medical sector, along with its market prices, production costs, trade, etc. Hence, the industrial tapespimycin procurement is governed by the variations observed in its prices, shifts in its demand in the healthcare sector and supply across various regions around the world.

Raw Material for Tanespimycin Production

According to the tanespimycin manufacturing plant project report, the key raw material for tanespimycin production includes corn.

Manufacturing Process of Tanespimycin

The extensive tanespimycin production cost report consists of the major industrial manufacturing process:

• By Fermentation: The production process of tanespimycin is carried out by fermenting corn in a culture medium. Initially, corn is processed and fermented using Streptomyces hygroscopicus as a bacterial constraint. The fermentation yields geldanamycin as an intermediate. The intermediate is then modified through a semi-synthetic process involving the substitution of the methoxy group in geldanamycin with an amine group and produces tanespimycin at the end.

Tanespimycin, also known as 17-AAG (17-allylamino-17-demethoxygeldanamycin), is a small-molecule inhibitor of Hsp90 (heat shock protein 90). It is a semi-synthetic derivative of the natural substance geldanamycin, which was obtained from the bacteria Streptomyces hygroscopicus. The structural formula of Tanespimycin is C31H43N3O8 and its molecular weight is 585.69 g/mol. It has a melting point ranges between 226-230°C. It is stable under normal conditions but is sensitive to light and heat.